This advert is not available!
The laboratory of professor Carlos Ibanez is now seeking a talented and enthusiastic researcher with expertise in medicinal chemistry and chemical biology to advance drug discovery efforts and investigations on death receptor signaling and physiology in cancer and neuronal cells.
The research entails medicinal chemistry studies on small molecules targeting the p75NTR death receptor identified in our ongoing screens, with the objective to improve the pharmacokinetic and biological properties of chemical leads. Please see Goh et al. (2018) Cell Chemical Biology 25, 1485–1494 for a representative publication of this work (carlosibanezlab.se/Publications).
Funding is available for an initial period of 3 to 4 years, starting during the first half of 2019.
Entry requirements
Candidates will be accepted at the postdoctoral level with a PhD awarded within the last 3 years. Strong and documented expertise in medicinal chemistry and chemical biology is a requirement for consideration. The successful candidate is expected to be sufficiently independent to formulate questions, design experiments and perform research. Excellent command of the English language is required.
Qualified to be employed as a postdoctor is one who has obtained a doctorate or has equivalent scientific competence.
Application process
An employment application must contain the following documents in English or Swedish:
Applicants should arrange to have at least two confidential letters of reference sent independently by referees to this email address.
The application is to be submitted through the Varbi recruitment system no later than April 30th.
Type of employment | Temporary position |
---|---|
Contract type | Full time |
First day of employment | as soon as possible upon agreement |
Salary | monthly salary |
Number of positions | 1 |
Full-time equivalent | 100 |
City | Stockholm |
County | Stockholms län |
Country | Sweden |
Reference number | 2-2310/2019 |
Contact |
|
Published | 11.Apr.2019 |
Last application date | 30.Apr.2019 11:59 PM CEST |